Richard Furman
Overview
Explore the profile of Richard Furman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1095
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dubovsky J, Beckwith K, Natarajan G, Woyach J, Jaglowski S, Zhong Y, et al.
Blood
. 2013 Jul;
122(15):2539-49.
PMID: 23886836
Given its critical role in T-cell signaling, interleukin-2-inducible kinase (ITK) is an appealing therapeutic target that can contribute to the pathogenesis of certain infectious, autoimmune, and neoplastic diseases. Ablation of...
12.
OConnor O, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al.
J Clin Oncol
. 2011 Jan;
29(9):1182-9.
PMID: 21245435
Purpose: Peripheral T-cell lymphoma (PTCL) is a poor prognosis subtype of non-Hodgkin's lymphoma with no accepted standard of care. This study evaluated the efficacy and tolerability of pralatrexate, a novel...
13.
van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, et al.
J Clin Oncol
. 2010 Jul;
28(23):3701-8.
PMID: 20625121
Purpose: Interleukin-6 (IL-6) has emerged as a key factor in the pathogenesis of the atypical lymphoproliferative disorder Castleman's disease (CD). Siltuximab is a new anti-IL-6, chimeric monoclonal antibody with potential...
14.
Elstrom R, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, et al.
Clin Lymphoma Myeloma Leuk
. 2010 Jun;
10(3):192-6.
PMID: 20511164
Background: Patients with diffuse large B-cell lymphoma (DLBCL) who are not cured by initial therapy sometimes experience disease-free survival after autologous stem cell transplantation. Chemotherapy responsiveness before transplantation is a...
15.
Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, et al.
Cancer
. 2008 Mar;
112(10):2228-32.
PMID: 18338745
Background: Many patients with recurrent lymphoma are unable to tolerate intensive therapies, or have disease that is refractory. Metronomic chemotherapy offers a novel, potentially less toxic yet effective treatment strategy....
16.
Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, et al.
Leuk Lymphoma
. 2008 Feb;
49(3):447-50.
PMID: 18297520
The prednisone, etoposide, procarbazine and cyclophosphamide (PEP-C) oral combination chemotherapy regimen (prednisone 20 mg, cyclophosphamide 50 mg, etoposide 50 mg, and procarbazine 50 mg with an oral anti-emetic) was employed...
17.
Leonard J, Coleman M, Ketas J, Chadburn A, Furman R, Schuster M, et al.
Clin Cancer Res
. 2004 Aug;
10(16):5327-34.
PMID: 15328168
Purpose: We conducted a single-center, dose-escalation study evaluating the safety, pharmacokinetics, and efficacy of epratuzumab, an anti-CD22 humanized monoclonal antibody, in patients with aggressive non-Hodgkin's lymphoma. Experimental Design: Epratuzumab was...